F S&P 500
5,093.25 -10.75 (-0.21%) F Dow Jones
37,907.00 -86.00 (-0.23%) F Nasdaq
17,846.50 -29.75 (-0.17%) E-mini Russell 2000 Index Futur
1,986.50 -4.50 (-0.23%) Petróleo
85.86 +0.45 (+0.53%) Oro
2,403.80 +20.80 (+0.87%)
Dynavax Technologies Corporation (DVAX)
Fuera de horario:
Dynavax Technologies Corporation
2100 Powell Street
Suite 720
EmeryVille, CA 94608
United States
510 848 5100
https://www.dynavax.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 408
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Ryan Spencer | CEO, Interim CFO & Director | 1.25M | N/D | 1978 |
| Mr. David F. Novack | President & COO | 925.6k | N/D | 1962 |
| Ms. Kelly MacDonald | SVP & CFO (Leave of Absence) | 674.27k | N/D | 1984 |
| Mr. Justin Burgess | Principal Accounting Officer & Controller | N/D | N/D | N/D |
| Mr. Jeff P. Coon | CHRO and Senior VP of Human Resources & Administration | N/D | N/D | 1963 |
| Mr. Paul Cox | VP of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Mr. Donn Casale | Chief Commercial Officer | N/D | N/D | N/D |
| Dr. Dong Yu | Senior Vice President of Vaccine Research | N/D | N/D | N/D |
| Mr. Eric Frings | VP, Site Head & MD for Dynavax GmbH | N/D | N/D | N/D |
| Mr. Todd Lopeman | Senior Vice President of Technical Operations | N/D | N/D | N/D |
Descripción
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Dynavax Technologies Corporation a partir del 1 de abril de 2024 es 5. Las puntuaciones principales son Auditoría: 5; Junta: 5; Derechos del accionista: 7; Compensación: 3.
